Financial result for the consolidated six months ended September 30, 2025

Consolidated Financial Results (Tanshin)

for the Six Months Ended September 30, 2025 (Based on IFRS)

November 13, 2025

Name of listed company :CYBERDYNE, INC. Stock exchange listing :Growth Section of TSE

Stock code :7779 URL :https://www.cyberdyne.jp/english

Representative (title) :President and CEO Name :Yoshiyuki Sankai

Contact (title) :ＣＯＯ Name :Shinji Honda Tel. +81-29-869- 9981 Scheduled date for release of six-month report :November 13, 2025 Scheduled start of dividend payment :－ Additional materials for the financial results :yes

Information meeting for the financial results :yes (only for institutional investors)

(Millions of yen: Rounded to the nearest one million yen)

1. Consolidated financial results for the six months ended September 30, 2025 (April 1, 2025-Semtember 30, 2025)

   1. Consolidated result of operations (percentages denote year-on-year change)

      	Revenue		Operating profit (loss)		Profit (loss) before tax		Profit (loss) attributable to owners of parent
      Apr.1-Sep. 30, 2025 Apr.1-Sep. 30, 2024	1,963 2,143	％ (8.4) 1.9	(174) (497)	％ - -	297 (215)	％ - -	70 (305)	％ - -

      	Basic earnings (loss) per share	Diluted earnings (loss) per share
      Apr.1-Sep. 30, 2025	Yen 0.33	Yen 0.33
      Apr.1-Sep. 30, 2024	(1.45)	(1.45)

   2. Consolidated financial position

      	Total assets	Total equity	Total equity attributable to owners of the parent	Ratio of equity attributable to owners of the parent to total assets
      As of Sep. 30, 2025	Millions of yen 48,914	Millions of yen 39,612	Millions of yen 39,596	％ 81.0
      As of Mar 31, 2025	48,547	39,593	39,575	81.5

2. Dividends

   	Dividend payments for each term and the year
   	End of 1st quarter (June.30)	End of 2nd quarter (September.30)	End of 3rd quarter (December.31)	Fiscal year end (March.31)	Total
   Fiscal year ended March 31, 2025 Fiscal year ending March 31, 2026	Yen	Yen	Yen	Yen	Yen
   	- -	0.00 0.00	-	0.00	0.00

   Notes:

   1. Changes from the latest released dividend forecasts: none

   2. The table of "Dividends" indicates dividend payments on Common Shares. Dividends on Class Share (non-listed) for which the number of share units differs from Common Shares are shown below as "Dividends on Class Shares".

3. Forecast of consolidated financial results for the fiscal year ending March 31, 2026 (April 1, 2025-March 31, 2026)

   As the business of CYBERDYNE Inc. and its group companies (collectively referred to as the "Group") is based on a new market with innovative technologies, there are many uncertain factors that could have an impact on its performance and make it difficult for CYBERDYNE Inc. (the "Company") to provide a forecast with accurate figures. As such the Company will not announce the forecast of consolidated financial results.

   Notes:

   1. Changes in key subsidiaries during the consolidated three month period (changes in specific subsidiaries resulting in changes of consolidation scope): none

      new: － (company name: － ) , excluded: － (company name: － )

   2. Changes in accounting policies, accounting estimates, and restatement of error corrections

      1. Changes in accounting policies required by IFRS : none

      2. Changes in accounting policies due to reasons other than (ⅰ) : none

      3. Changes in accounting estimates: none

   3. Total number of issued shares (Common Shares)

      1. Total number of issued shares at the end of each period (including treasury shares)

         As of September 30, 2025

         215,145,809 shares

         As of March 31, 2025

         215,145,809 shares

      2. Total number of treasury shares at the end of each period

         As of September 30, 2025

         4,014,753 shares

         As of March 31, 2025

         4,014,753 shares

      3. Average number of shares during each three month period

Note: Class B Shares are ranked the same as Common Shares and paid the same amount as Common Shares with regard to dividends of surplus and distribution of residual assets. Therefore the total number of issued shares at each end of period and the average number of shares during each period include Class B Shares as Common Shares.

*This quarterly consolidated financial report is not subject to the quarterly review procedure by the scope of audit.

Dividends on Class Shares

Details of dividends on the Company's class shares for which the number of share units differs from its Common Shares are as below.

Note:

The Company issued Class B Shares which were accorded the same rights as its Common Shares with regard to dividends and distribution of residual assets, but for which share units differ from Common Shares.

• Contents of the Attached Material

  1. Qualitative information regarding settlement of accounts for the six months. 2

     1. Explanation of operating results. 2

     2. Explanation of financial position… 6

     3. Status of cash flow. 7

  2. Condensed quarterly consolidated financial statement (Unaudited) 8

     1. Condensed quarterly consolidated statement of financial position (Unaudited)… 8

     2. Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated statement of comprehensive income (Unaudited). 10

        Condensed year to quarter end consolidated statement of profit or loss… 10

        Condensed year to quarter end consolidated statement of comprehensive income. 11

     3. Condensed quarterly consolidated statement of changes in equity (Unaudited) 12

     4. Condensed quarterly consolidated statement of cash flows (Unaudited). 14

     5. Notes to condensed quarterly consolidated financial statements 15

(Notes on premise of going concern) 15

(Changes in accounting policy) 15

(Revenue) 16

1. Qualitative information regarding settlement of accounts for the six months ended September 30, 2025

   1. Explanation of operating results

      All forward-looking statements included in this explanation were determined reasonable by CYBERDYNE Inc. (the "Company") and its group companies (collectively referred to as the "Group") based on currently available information for the consolidated ended September 30, 2025, and certain assumptions made by the Group.

      To solve various issues facing society, the Group will make full use of "Cybernics" (a new field that integrates and combines human, robot, AI, and information systems) and handle HCPS (Human-Cyber-Physical Space) in a unified manner. Furthermore, through Cybernics, the Group promotes the realization of "Techno Peer Support" and future development by creating the "Cybernics Industry," a new industry that will follow the robotics and IT industries.

      The Group defines "Techno Peer Support Society" as a safe and secure society where people and technology coexist, cooperate and mutually support each other to enhance the independence and freedom of people of all generations and solve various problems in their lives both mentally and physically. To realize Techno Peer Support Society and Cybernics Industry, the Group is developing various Cybernics Technologies that improve, regenerate, expand, and support the wearer's physical functions.

      Status of business operation

      <>

      The Group is working to promote CYBERNICS Treatment, which utilizes the world's first wearable cyborg, HAL® (Hybrid Assistive Limb), to facilitate the improvement and regeneration of brain, nerve, and muscular functions, and to establish it as a global standard treatment.

      In a systematic review published in June 2025 in the international medical journal Global Spine Journal, HAL® was compared with nine other passively controlled exoskeleton-type devices (devices that repeatedly perform movements through robotic control). The results demonstrated that HAL® is the only device that induces neuroplasticity and provides comprehensive therapeutic effects across multiple health outcomes associated with spinal cord injury (SCI).

      The paper cites findings from functional MRI studies, which report that active movement elicits significantly greater neural activity in the central nervous system than passive movement. Furthermore, it discusses that the repetitive neuromuscular process established between the central and peripheral nervous systems-made possible by HAL®'s core principles-facilitates the learning and reinforcement of neural signaling in the brain and spinal cord, ultimately leading to the reconstruction and reactivation of spinal circuits below the site of spinal cord injury and the partial reinnervation of neural pathways.

      Through this mechanism of inducing neuroplasticity, HAL® demonstrated consistent improvement not only in primary mobility outcomes such as walking distance and speed but also in secondary outcomes such as urinary and bowel function (continence), pain reduction, and overall quality of life (QoL). These findings provide clinical evidence that HAL® is a unique therapeutic device offering a comprehensive treatment approach to the entire neuromuscular system.

      (Japan)

      The Group continues to develop Cybernics Treatment for progressive neuromuscular disease patient where there is no established treatment method. Post-marketing surveillance on the Medical HAL Lower Limb Type Double-leg Model suggested a high efficacy and safety towards progressive neuromuscular diseases, for which no effective treatment methods are available in the medical world yet. Based on the extremely high

      efficacy and safety results obtained in post-market surveillance, Medical HAL Lower Limb Type was given increased points after the 2022 revision of medical treatment fees as "a remarkable functional improvement effect unprecedented in patients with progressive neuromuscular diseases for which no other effective treatment methods have been established, including already approved drugs" (excerpt from the medical technology evaluation proposal by the Japanese Society for Neurological Therapeutics).

      Regarding spinal cord-related diseases, the Japanese Minister of Health, Labor, and Welfare ("MHLW") approved additional indications of HTLV-1-associated myelopathy (HAM) and hereditary spastic paraplegia for HAL on October 2022 and public health insurance is available in Japan from October 2023. Regarding traumatic spinal cord injuries, the Company is consulting with the regulators on the necessary steps to obtain medical device approvals.

      Regarding stroke, the Company discussed the result of the investigator-initiated clinical trial using the Medical HAL Lower Limb Type single-leg model (HIT2016 trial). Considering the practice conditions surrounding acute stroke treatment and recovery rehabilitation, the Company is preparing additional studies (clinical trials).

      In January 2025, the small-size model of the Medical HAL Lower Limb Type was approved as a medical device for the same target diseases as the conventional model. With the approval of this small-size HAL, Cybernics Treatment has become available for patients with an estimated height of 100 cm to 150 cm, who previously had difficulty using the conventional model (intended for those 150 cm or taller). Following its approval in Japan, the United States, and Europe, the Company will continue its efforts to obtain its medical device certification worldwide and accelerate the business expansion of Medical HAL.

      Based on favorable results in a pilot study demonstrating improved motor function in patients with Parkinson's disease, the Company is preparing to conduct clinical trials for the approval of HAL "Lumbar Type" as a medical device.

      (USA)

      As a medical service platform for individuals, the Company's subsidiary, RISE Healthcare Group (RHG), operates mainly in Southern California, with five facilities offering Cybernics Treatment using HAL®.

      In May 2024, the U.S. FDA granted, for the first time globally, marketing clearance for the small-size model of Medical HAL and approved an additional indication for cerebral palsy (age 12 and older). It also approved the expansion of indications to include HAM and hereditary spastic paraplegia, which were already approved in Japan.

      Based on accumulated treatment experience in the U.S., along with the approval of the small-size model and expansion of target diseases, the Company will develop future business through both individual medical service offerings and product rental services for Medical HAL.

      (EMEA: Mainly Europe and the Middle East)

      The Group continues to expand Cybernics Treatment in the region. In Italy, 36 units of the HAL® series have been introduced to Coopselios, a major social cooperative specializing in medical and nursing care services, with plans to further expand the number of units in the future.

      In Turkey, alongside the growth of medical tourism, interest in CYBERNICS technology has been rapidly increasing, and HAL® is currently in operation at four facilities across the country.

      In November 2024, the Company received an order for HAL series and other Cybernics products as part of the Ukraine Emergency Recovery and Reconstruction Project by the Japan International Cooperation Agency (JICA). Delivery for installation at a medical facility in Kyiv, Ukraine's capital, was completed in March 2025, where the devices are expected to aid in the treatment of individuals injured in the war. In addition, HAL® has been installed in Portugal.

      In Germany, the G-BA (German Federal Joint Committee), the public health insurance authority, decided to conduct a clinical trial for spinal cord injury treatment under public insurance coverage. CRO selection has been completed, and preparations, including site selection, are underway.

      In December 2024, the small-size model of Medical HAL obtained medical device certification under the new European Medical Device Regulation (MDR). The Company will continue promoting the expansion of Cybernics Treatment in Europe, including the small-size model.

      (APAC: Asia Pacific)

      CYBERDYNE MALAYSIA Sdn. Bhd. continues to promote Cybernics Treatment across Southeast Asia, India, Australia, and Taiwan.

      In Malaysia, the partnership with the government-affiliated Social Security Organization (PERKESO) has been further strengthened, expanding access to Cybernics Treatment under PERKESO coverage. In May 2024, top-level meetings were held at the Company's headquarters with the Malaysian Minister of Human Resources and other officials, where the Minister expressed the intention to install HAL products at the National Neuro-Robotics and Cybernics Rehabilitation Centre. In December 2024, the Company signed a contract with PERKESO valued at approximately USD 4.6 million (around JPY 700 million at an exchange rate of 150 JPY/USD) for a maximum of five years, and installation of 50 sets (65 units) was completed in August 2025. PERKESO has also officially announced plans to build a new center as the next project for the facility, and discussions on introducing HAL to this new site will follow.

      For the expansion into Taiwan, following the signing of a strategic partnership agreement in March 2025 with the Development Center for Biotechnology, Fu Jen Catholic University, Fu Jen Catholic University Hospital, and the Center for Cybernics Research at the University of Tsukuba, an MOU for international collaboration was also concluded in June 2025 with National Taiwan University and the University of Tsukuba. In November 2025, a symposium on Cybernics Medical and Healthcare Innovation was co-hosted with National Taiwan University, and based on this achievement, the Group will further promote the business development in the region.

      <>

      The Group has developed various types of HAL for seniors to improve their physical function, prevent illness and frailty, and reduce the requirement for care. These include the HAL Lower Limb Type for enhancing the ability to walk, the HAL Single Joint Type to train elbow, knee, and ankle movements, and the HAL Lumbar Type to train the trunk and lower limb function.

      (Service at facilities for individuals)

      The Group continues to offer Neuro HALFIT, a program that induces improvement of the brain-nerve and musculoskeletal system through utilizing HAL. The program is currently available at 18 Robocare Centers operated by business partners. The Group plans to open additional Robocare Centers.

      (Neuro HALFIT at Home as a service towards individuals)

      Neuro HALFIT at Home is a home-based program where individuals rent HAL and engage in HAL-assisted workouts at Home. The HAL Monitor, linked to Cyberdyne's cloud, visualizes bio-electrical signals that command body movements and posture information and enables the wearer to obtain visual feedback. In addition to providing online support by therapists, trainers, and other professional staff, the Company also works with home-based service providers to promote in-person support, from setting up equipment at home to implementing programs.

      <>

      The Company is developing and commercializing the "Cyvis" series, which collects, analyzes, and AI-processes medical and healthcare data daily to provide optimized health management, disease prevention, diagnosis, and treatment programs tailored to each individual. One of the products in this series, the "Compact Holter ECG Medical Vital Sensor Cyvis M100," obtained medical device certification in November 2024.

      Cyvis can measure not only cardiac activity data but also body surface temperature and acceleration, etc. Operational verification is underway not only for medical institutions but also for welfare facility residents and workers. The Company plans to gradually expand its capabilities such as SpO2.

      Furthermore, the Company will continue to develop and commercialize new devices capable of collecting other medical and healthcare data.

      <> (Well-being)

      Since 2021, the Company has been operating the HAL Lumbar Type in nursing care facilities in Hampshire, U.K., as a model case to spread its usage to other areas in the U.K. and other European countries.

      (Labor Support, Disinfection, and Cleaning)

      Regarding the next-generation Cleaning Robot CL02, which uses cutting-edge SLAM technology to achieve high-speed autonomous driving, the Group works with major construction companies with its ability to ride on elevators automatically and connect with cloud systems; the companies are developing this technology as a solution to make building management smarter and reduce management costs. Furthermore, the company is expanding its mobility part as a transportation robot inside the factory.

      Status of Research and Development

      The Group develops"Acoustic X,"a patented photoacoustic imaging system based on the LED light source method that realizes real-time, high-resolution 3D imaging of blood vessels and blood in the peripheral organs without needing contrast agents. The Group develops this technology as a next-generation medical image diagnosis device. In addition, research is underway at prominent medical institutions and research facilities around the globe to create various applications for this technology.

      Furthermore, the proposal of the Group was selected in 2023 for the next Cross-ministerial Strategic Innovation Promotion Program (SIP) Third Phase: Development of Fundamental Technologies, the Establishment of Common Systems, Rules, and Regulations for the Expansion of Human Collaborative Robotics, Theme 6: Development of Social Implementation Technologies for HCPS* Integrated Human Collaborative Robotics to Solve Social Issues" that is led by the Cabinet Office of Japan. Under this program, the Group continues to (i) develop an application for various living spaces such as residences, facilities, and workplaces, (ii) utilize HCPS-integrated Cybernics master remote control technology that works together with human information (physiological, physical, behavioral, cognitive, psychological, etc.), (iii) acquire and utilize human information obtained through non-invasive HCPS-integrated human-collaborative robotics, and

      (iv) Establish links with other related technologies of the R&D theme to improve the independence and freedom of seniors and people with limited access to transportation.

      At the Tonomachi International Strategic Zone (King Sky Front) in Kawasaki City, Cybernics Medical Innovation Base Building A functions to promote the systematization of Cybernics Treatment by combining HAL with regenerative medicine and drugs and the development of technologies that integrate medical and bio-related technologies with AI, robotics and information systems. The Company will continue coordinating with its C-Startup partners in regenerative medicine and drug creation.

      Numbers of operating units

      As of the end of September 2025, 543 Medical HAL® Lower Limb Type units were operating worldwide, including those used for clinical research. 114 units were used in Japanese hospitals for treatment. In addition, there were 704 units of HAL® Single Joint Type, mainly from the increase of products for medical use. 362 units of HAL® for Well-being Lower Limb Type and HAL® for Living Support Lower Limb Type (older model) were in operation. Furthermore, 1,072 units of HAL® Lumbar Type for Well-being were in operation. In addition, there were 406 units of HAL® Lumbar Type for Labor Support and 181 units of Cleaning Robots and Transportation Robots.

      In the consolidated six months that ended September 30, 2025, an increase in medical service in the Europe contributed to the revenue recorded at ¥1,963 million (8.4% decrease year on year). In addition, the Group recorded a gross profit of ¥1,222 million (15.1% increase year on year).

      The Group recorded research and development expenses at ¥437 million (7.1% increase year on year), mainly due to developing new products at the Company's own cost, clinical research, and consigned research projects. In addition, the Group recorded other selling, general, and administrative expenses at ¥1,187 million (13.0% decrease year on year) due to a decrease in advertising expenses and purchases of consumables.

      Other income was recorded at ¥284 million (29.1% increase year on year), mainly from a consigned research project, resulting in an operating loss of ¥174 million (65.0% decrease year on year).

      The Group recorded a finance income of ¥627 million, mainly due to gains from the valuation difference of investment securities, finance costs were ¥261 million, mainly due to the provision for allowance for doubtful accounts and other factors. In addition, the Group recorded gains related to CEJ Fund at ¥109 million and income tax expense at ¥229 million from deferred tax expenses, resulting in the posting of loss attributable to owners of the parent at ¥70 million (¥305 million loss in the same period of the previous year).

      The Company forms business and capital alliances with various startup companies that develop unique technologies. The Company calculates the fair value of unlisted stocks of such companies using the IFRS 9 Financial Instruments. As a result, during the consolidated six months ended September 30, 2025, The Group recorded ¥657 million in the gain on valuation difference of investments securities as finance income and gains related to CEJ Fund. A valuation loss of ¥21 million on investment securities was included in finance costs and loss related to the CEJ Fund. Furthermore, the Group posted ¥225 million from deferred tax expense associated with this valuation as an income tax expense and reclassified ¥94 million to third-party interest in CEJ Fund. As a result, the impact of calculating the fair value gain for the six-month period was ¥505 million.

   2. Explanation of financial position

      ① Assets

      For the consolidated six months ended September 30, 2025, assets increased ¥367 million to ¥48,914 million compared to the end of the previous fiscal year. Changes were mainly due to a decrease of ¥2,513 million in cash and cash equivalent, partially offset by an increase of ¥2,740 million in other financial assets (current) and ¥445 million in other financial assets (non-current).

      ② Liabilities

      For the consolidated six months ended September 30, 2025, liabilities increased ¥348 million to ¥9,302 million compared to the end of the previous fiscal year. The changes were mainly due to an increase of ¥59 million in trade and other payables and ¥220 million in deferred tax liabilities.

      ③ Equity

      For the consolidated six months ended September 30, 2025, equity increased ¥19 million to ¥39,612

      million compared to the end of the previous fiscal year. Changes were mainly due to an increase in retained earnings following the posting of gain attributable to the owners of the parents.

   3. Status of cashflow

      For the consolidated six months ended September 30, 2025, cash and cash equivalents decreased ¥2,513 million to ¥4,311 million compared to the end of the previous fiscal year. The main influence factors for the cash flow status within the consolidated six months ended September 30, 2025, are stated below.

      (Cash flows from operating activities)

      For the consolidated six months ended September 30, 2025, net cash provided by operating activities recorded an inflow of ¥362 million (an outflow of ¥72 million in the previous consolidated six months). Changes were mainly due to finance income posted at ¥627 million, and gains on CEJ Fund recorded at ¥109 million, partially offset by Depreciation and amortization recorded at ¥308 million, trade and other receivables posted at ¥321 million and finance costs posted at ¥261 million.

      (Cash flows from investment activities)

      For the consolidated six months ended September 30, 2025, net cash used in investing activities recorded an outflow of ¥2,794 million (an outflow of ¥791 million in the consolidated six months of the previous fiscal year). The changes were mainly due to the proceeds of redemption of investments posted at ¥7,984 million, partially offset by the purchase of investments posted at ¥10,000 million and the Payments into time deposits posted at ¥744 million.

      (Cash flows from financing activities)

      For the consolidated six months ended September 30, 2025, net cash used in financing activities recorded an outflow of ¥97 million (an outflow of ¥95 million in the consolidated six months of the previous fiscal year). The changes were mainly due to the outflow of ¥85 million from Lease liabilities paid.

2. Condensed quarterly consolidated financial statement

   1. Condensed quarterly consolidated statement of financial position (Unaudited)

      As of March 31, 2025 As of September 30, 2025

      Millions of yen Millions of yen

      Assets

      Current assets

      Cash and cash equivalents	6,824		4,311
      Trade and other receivables	800		480
      Other financial assets	8,033		10,773
      Inventories	923		1,021
      Other current assets	177		234
      Total current assets	16,758		16,819
      Non-current assets
      Operating lease assets	353		324
      Property, plant and equipment	13,186		13,104
      Right of use assets	362		376
      Goodwill	1,766		1,759
      Intangible assets	45		39
      Investments accounted for using equity method	243		240
      Other financial assets	15,333		15,778
      Other non-current assets	501		475
      Total non-current assets	31,790		32,095
      Total assets	48,547		48,914

      As of March 31, 2025 As of September 30, 2025

      Millions of yen Millions of yen

      Liabilities and equity Liabilities

      Current liabilities

      Trade and other payables	533		592
      Bonds and borrowings	22		19
      Lease liabilities	146		140
      Other current liabilities	384		436
      Total current liabilities	1,085		1,187
      Non-current liabilities
      Bonds and borrowings	15		15
      Third-party interests in CEJ Fund	5,165		5,176
      Lease liabilities	251		268
      Provisions	193		191
      Deferred tax liabilities	2,202		2,422
      Other non-current liabilities	43		43
      Total non-current liabilities	7,869		8,115
      Total liabilities	8,954		9,302
      Equity
      Share capital	10		10
      Capital surplus	42,297		42,297
      Treasury shares	(1,188)		(1,188)
      Other components of equity	(743)		(792)
      Retained earnings	(801)		(731)
      Total equity attributable to owners of the parent	39,575		39,596
      Non-controlling interests	18		16
      Total equity	39,593		39,612
      Total liabilities and equity	48,547		48,914

   2. Condensed quarterly consolidated statement of profit or loss and condensed quarterly consolidated statement of comprehensive income (Unaudited)

      Condensed year to quarter end consolidated statement of profit or loss
      	Six months ended		Six months ended
      	September 30, 2024		September 30, 2025
      	Millions of yen		Millions of yen
      Revenue	2,143		1,963
      Cost of sales	(1,081)		(742)
      Gross profit	1,062		1,222
      Selling, general and administrative expenses
      Research and development expenses	(408)		(437)
      Other selling, general and administrative expenses	(1,365)		(1,187)
      Total selling, general and administrative expenses	(1,774)		(1,625)
      Other income	220		284
      Other expenses	(5)		(55)
      Operating profit (loss)	(497)		(174)
      Finance income	340		627
      Finance costs	(173)		(261)
      Gains related to CEJ Fund	127		109
      Share of profit (loss) of investments accounted for using equity method	(11)		(4)
      Profit (loss) before tax	(215)		297
      Income tax expense	(171)		(229)
      Profit (loss)	(385)		68
      Profit (loss) attributable to
      Owners of parent	(305)		70
      Non-controlling interests	(80)		(3)
      Profit (loss)	(385)		68
      Earnings (loss) per share
      Basic earnings (loss) per share (yen)	(1.45)	0.33
      Diluted earnings (loss) per share (yen)	(1.45)	0.33

      Condensed year to quarter end consolidated statement of comprehensive income

      Six months ended September 30, 2024

      Six months ended September 30, 2025

      Millions of yen Millions of yen

      Profit (loss) (385) 68

      Other comprehensive income

      Items that will not be reclassified to profit or loss Financial assets measured at fair value through other comprehensive income

      32 (18)

      Total of items that will not be reclassified to profit or loss 32 (18)

      Items that may be reclassified to profit or loss

      Exchange differences on translation of foreign operations	(56)		(25)
      Total of items that may be reclassified to profit or loss	(56)		(25)
      Total other comprehensive income, net of tax	(24)		(43)
      Comprehensive income	(410)		25
      Comprehensive income attributable to Owners of parent	(331)		27
      Non-controlling interests	(78)		(3)
      Comprehensive income	(410)		25

   3. Condensed quarterly consolidated statement of changes in equity (Unaudited)

Six months ended September 30, 2024 (from April 1, 2024 to September 30, 2024)

Equity attributable to owners of parent

Other components of equity

Equity attributable to owners of parent Other

Non-controlling

Total equity

components of equity

Total

Retained Total earnings

interests

Six months ended September 30, 2025 (from April 1, 2025 to September 30, 2025)

Equity attributable to owners of parent

Other components of equity

Equity attributable to owners of parent Other

Non-controlling

Total equity

components of equity

Total

Retained Total earnings

interests

1. Notes to condensed quarterly consolidated financial statements (Notes on premise of going concern)

   There are no items to report.

   (Segment information)

   1. Service transferred over time

      The Group's reportable segments are the components of the Group for which discrete financial information is available and which are regularly reviewed by the Board of Directors in deciding how to allocate resources and assess their performance. Since the Group operates under a single segment of business related to robotics, segment information is omitted.

   2. Revenue and results of reportable segments

      Since the Group operates under a single segment, segment information is omitted.

   3. Information about Products and Services

Please refer to the Note "Revenue" for information related to products and services.

(Revenue)

Disaggregation of revenue

Details of disaggregation of revenue are set forth below.

Six months ended September 30, 2024

Six months ended September 30, 2025

Millions of yen Millions of yen

(Note) Since the Group operates under a single segment of business, segment information on revenue is omitted.

Service transferred over time

Service transferred over time includes rental income based on the individual rental contract, maintenance income based on the maintenance contract concerning finance lease income where the Group acts as a lessor of right-of-use asset and subscription fees from the provision and operation of smartphone applications.

The Group recognizes rental income as income generated throughout the rental period after the customer accepts the relevant product by either of the following methods. Pay-per-use model based on times of product usage in the applicable month or base fee model based on the fixed monthly price.

The Group recognizes maintenance income as a performance obligation satisfied over time. Accordingly, the Company records this revenue during this contract period based on the average amount during the period.

The Group recognizes subscription fees for the provision and operation of smartphone applications as service provided through an application over time. The Company records this revenue over time.

The Group recognizes sponsorship revenue by providing the right to indicate sponsorship through a title sponsorship contract over a fixed time.

Asset transferred at a point of time

The asset transferred at a point of time includes revenue from sales of commodities and products based on the sales contract. The Group mainly determines that performance obligation of sales of commodities and products are satisfied at the point of customer acceptance of the relevant product. Therefore, the Group receives most of the payment within one month from the point of fulfilling the performance obligation. Regarding transaction price, there is no significance in the amount of sales revenue that includes variable consideration. Furthermore, there are no significant financial components in the amount of promised consideration.

Furthermore, if the Group acts as a lessor of right-of-use of its devices such as HAL, the Group classifies the relevant lease as a finance lease. Finance lease income is processed in the same way as cases where the Group acts as a lessor of manufacturer or distributor of sales of goods. The Group determines that performance obligation is satisfied at the point of customer acceptance, and the revenue is recognized at a point of time.

Service transferred at a point of time

Service transferred at a point of time includes revenue from offering Cybernic Treatment and training service at Cybernic Treatment Center and Robocare Centers to end-users (such as patients). In addition, the Company also includes revenue received in return for providing outcomes of consigned research projects in this category.

The Group determines that the performance obligation of Cybernic Treatment and training services are satisfied at the point of completion of such services. Furthermore, the Group determines that the performance obligation of providing outcomes of consigned research projects is satisfied when the customer inspects and accepts the work.